Axogen, Inc. - Common Stock (AXGN)

55.75
-0.60 (-1.06%)
NASDAQ · Last Trade: Nov 21st, 1:35 PM EST
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors

Detailed Quote

Previous Close56.35
Open55.71
Bid55.76
Ask57.58
Day's Range55.03 - 56.91
52 Week Range25.16 - 59.72
Volume876,067
Market Cap2.31B
PE Ratio (TTM)-85.77
EPS (TTM)-0.7
Dividend & YieldN/A (N/A)
1 Month Average Volume2,038,687

Chart

About Axogen, Inc. - Common Stock (AXGN)

Axogen Inc is a leading provider of innovative surgical solutions for peripheral nerve repair and regeneration. The company specializes in the development and commercialization of advanced medical technologies designed to support nerve repair procedures, particularly in cases of nerve injuries resulting from trauma, surgery, or other medical conditions. By offering a range of products and services, Axogen aims to improve patient outcomes and enhance the quality of life for individuals suffering from nerve damage. Their solutions include biologically designed grafts and additional support products that facilitate the healing process and promote functional recovery. Read More

News & Press Releases

Axogen (NASDAQ:AXGN) Clears the Minervini Trend Template, but Setup Quality Still Demands Patiencechartmill.com
Via Chartmill · November 21, 2026
AxoGen: 3 Key Takeaways for Long-Term Investorsfool.com
The NerveTape acquisition opens a surgical market that represents 40-50% of nerve procedures, a structural expansion beyond its core transplant business.
Via The Motley Fool · November 16, 2026
Axogen, Inc. to Participate in Multiple Upcoming Investor Conferences
ALACHUA, Fla. and TAMPA, Fla., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (Nasdaq: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today announced that management is scheduled to participate in three upcoming investor conferences:
By Axogen, Inc. · Via GlobeNewswire · November 3, 2026
AxoGen Q3 Earnings Call Highlightsmarketbeat.com
AxoGen (NASDAQ:AXGN) reported third-quarter revenue growth of 26.2% as demand for its nerve-repair products increased across its breast, extremities, oral and maxillofacial, and head-and-neck markets. The company also raised its full-year revenue outlook following the October acquisition of BioCircu
Via MarketBeat · October 28, 2026
Axogen (NASDAQ:AXGN) Stock Jumps on Q3 Earnings Beat and Strong 2026 Revenue Guidancechartmill.com
Via Chartmill · October 28, 2026
Axogen (NASDAQ:AXGN) Shares Slide After Q2 Earnings Miss Overshadows Revenue Beat and Raised Guidancechartmill.com
Via Chartmill · July 29, 2026
Axogen Inc. (NASDAQ:AXGN) Achieves a Perfect Technical Score and Strong Fundamental Growthchartmill.com
Via Chartmill · June 20, 2026
Top US Stock Movers in Today's Sessionchartmill.com
Via Chartmill · October 28, 2026
Axogen (AXGN) Q3 2026 Earnings Call Transcriptfool.com
Breast segment surged 60% while BioCircuit acquisition expands nerve repair market reach.
Via The Motley Fool · October 28, 2026
US Top Movers: Biggest Gainers and Decliners in Today's Sessionchartmill.com
Via Chartmill · October 28, 2026
Oct. 28 Gap Stocks: Double-Digit Gap-Up and Gap-Down Moverschartmill.com
Via Chartmill · October 28, 2026
Premarket Movers for Oct. 28, 2026: Gainers and Loserschartmill.com
Via Chartmill · October 28, 2026
Axogen, Inc. Reports Third Quarter 2026 Financial Results
Raises Full Year Revenue Guidance to at Least 29% Growth or $290 million
By Axogen, Inc. · Via GlobeNewswire · October 28, 2026
Axogen, Inc. to Report Third Quarter 2026 Financial Results on October 28, 2026
ALACHUA, Fla. and TAMPA, Fla., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (Nasdaq: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today announced that it will release financial results for the third quarter of 2026 on Wednesday, October 28, 2026. Axogen management will host an investment-community conference call and webcast at 8:00 a.m. ET following the release.
By Axogen, Inc. · Via GlobeNewswire · October 14, 2026
Wound Care Stocks Are Posting Double-Digit Growth. Here’s Why.
RENO, Nev., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Wall Street Investor News Commentary - The global advanced wound care market is valued at $13.37 billion in 2025 and is projected to reach $19.32 billion by 2030, a compound annual growth rate of 7.6%, according to MarketsandMarkets. The firm points to chronic disease, an aging population and traumatic injuries as the main drivers, noting that diabetic foot ulcers affect roughly a quarter of patients with diabetes and are a leading cause of hospitalization. Active Companies from around the markets with current developments this week include: Conexeu Sciences Inc. (Nasdaq: CNXU), Solventum Corporation (NYSE: SOLV), Vericel Corporation (Nasdaq: VCEL), Axogen, Inc. (Nasdaq: AXGN), Eli Lilly and Company (NYSE: LLY).
By Wall Street Investor · Via GlobeNewswire · October 6, 2026
Axogen Completes Acquisition of BioCircuit Technologies, Adding NerveTape™, the First FDA Cleared Device for Sutureless Peripheral Nerve Repair
ALACHUA, Fla. and TAMPA, Fla., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (“Axogen” or the “Company”) (Nasdaq: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today announced that it has completed its previously announced acquisition of BioCircuit Technologies, Inc. (“BioCircuit”), a privately held medical device company and developer of NerveTape™.
By Axogen, Inc. · Via GlobeNewswire · October 1, 2026
3 Emerging Biotech Stocks With Significant Upside Potentialmarketbeat.com
Delcath Systems, Viking Therapeutics and AxoGen show growth potential backed by analyst Moderate Buy ratings and strong institutional ownership, despite risks like dilution and patent cliffs.
Via MarketBeat · September 30, 2026
Axogen Announces Pricing of $208.7 Million Public Offering of Common Stock
ALACHUA, Fla. and TAMPA, Fla., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (“Axogen” or the “Company”) (Nasdaq: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today announced the pricing of an underwritten public offering of 4,910,000 shares of its common stock at a price to the public of $42.50 per share, before underwriting discounts and commissions. All of the shares to be sold in the proposed offering are to be sold by Axogen. In addition, Axogen has granted the underwriters a 30-day option to purchase up to an additional 736,500 shares of its common stock at the public offering price, less underwriting discounts and commissions. The gross proceeds to Axogen from the proposed offering, before deducting underwriters’ discounts and commissions and other offering expenses payable by Axogen, are expected to be approximately $208.7 million (assuming no exercise of the underwriters’ option to purchase additional shares). The proposed offering is expected to close on September 11, 2026, subject to the satisfaction of customary closing conditions.
By Axogen, Inc. · Via GlobeNewswire · September 10, 2026
Axogen Enters into Definitive Agreement to Acquire BioCircuit Technologies
Acquisition adds NerveTape™, the 1st FDA-approved device for sutureless peripheral nerve repair, broadening Axogen’s addressable market within its focus markets
By Axogen, Inc. · Via GlobeNewswire · September 10, 2026
Axogen, Inc. to Participate in the 24th Annual Morgan Stanley Global Healthcare Conference
ALACHUA, Fla. and TAMPA, Fla., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today announced that management will be available for one-on-one investor meetings at the 24th Annual Morgan Stanley Global Healthcare Conference on Tuesday, September 15, 2026.
By Axogen, Inc. · Via GlobeNewswire · September 1, 2026
Cosmetic Surgery's Next Debate: Rebuild Tissue, Not Fill It
News Provided by Biotech Insider on behalf of Conexeu Sciences Inc.
By Biotech Insider · Via GlobeNewswire · August 11, 2026
Axogen (AXGN) Q2 2026 Earnings Call Transcriptfool.com
Breast segment revenue surged over 50% year over year, driving accelerated growth.
Via The Motley Fool · August 7, 2026
AxoGen Q2 Earnings Call Highlightsmarketbeat.com
AxoGen (NASDAQ:AXGN) reported second-quarter 2026 revenue of $69.7 million, up 23.1% from a year earlier, as demand for its Avance nerve graft and broader product portfolio increased across its target markets. The company raised its full-year revenue outlook to at least $279 million, representing gr
Via MarketBeat · July 29, 2026
Axogen, Inc. Reports Second Quarter 2026 Financial Results
Raises Full Year Revenue Guidance to at Least 24% Growth or $279 million
By Axogen, Inc. · Via GlobeNewswire · July 29, 2026
Axogen, Inc. to Report Second Quarter 2026 Financial Results on July 29, 2026
ALACHUA, Fla. and TAMPA, Fla., July 15, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (Nasdaq: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today announced that it will release financial results for the second quarter of 2026 on Wednesday, July 29, 2026. Axogen management will host an investment-community conference call and webcast at 8:00 a.m. ET following the release.
By Axogen, Inc. · Via GlobeNewswire · July 15, 2026